Carregant...
Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop
The recent advent of myriad targeted therapies for acute myeloid leukemia (AML) has led to new hope for our patients but has also introduced new challenges in managing the disease. For clinicians, the ability to treat AML in the outpatient setting with novel agents of equal or greater efficacy than...
Guardat en:
| Publicat a: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7727512/ https://ncbi.nlm.nih.gov/pubmed/33275692 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2020000089 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|